Ardea Biosciences, Inc. Board Of Directors Under Investigation For Potential Breaches Of Fiduciary Duty By Law Offices Of Howard G. Smith

Law Offices of Howard G. Smith announces that it is investigating potential claims against the Board of Directors of Ardea Biosciences, Inc. (“Ardea” or the “Company”) (NASDAQ: RDEA) related to the proposed acquisition of the Company by AstraZeneca. The transaction is valued at approximately $1.26 billion or $32 per share.

This investigation concerns whether the Board of Directors of Ardea breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Further, at least one analyst has set a target price for the Company’s stock at $40.00 per share.

If you are a shareholder of Ardea, if you have information or would like to learn more about our investigation, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to, or visit our website at

Copyright Business Wire 2010

If you liked this article you might like

AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends

AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends

10 Stocks That Fidelity Funds Are Buying

Thursday's Top 10 Articles, Videos on TheStreet

5 Stocks Insiders Love Right Now